Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are a pillar of cancer therapy with demonstrated efficacy in a variety of malignancies. However, they are associated with immune-related adverse events (irAEs) that affect many...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
